Read more
3:54 PM · 17 April 2024

Sage Therapeutics craters over 20% on study results

-
-
Open account Download free app

Shares of Sage Therapeutics (SAGE.US) are plunging today. Company is one of the worst performing Wall Street stocks today, plunging over 20% at press time. The move lower was triggered after company released results of mid-stage study of its experimental dalzanemdor treatment for Parkinson's disease. Company said that the study failed to meet its main goal and did not show any statistically significant differences between the treatment and placebo. 

Sage Therapeutics said that it does not plan any further development of dalzanemdor treatment for Parkinson's disease. Results of the Phase 2 studies in Huntington's and Alzheimer's diseases are expected in the later part of 2024.

Taking a look at Sage Therapeutics (SAGE.US) chart at D1 interval, we can see that the stock has recently plunged below the $16.50 support zone and continues to move lower. A massive plunge today pushed the stock below $11 per share for the first time in history. However, a part of the drop has been recovered and the stock trades off the daily lows now.

Source: xStation5

20 March 2026, 2:06 PM

SAP loses 4% despite positive recommendation at Bernstein 📉

19 March 2026, 6:27 PM

Ryanair at 5-month low 🚩Jet fuel price surge pressures aerospace industry

19 March 2026, 3:46 PM

Wall Street tries to stop the sell-off as oil surges 🚩Alibaba drops 7% amid earnings miss

19 March 2026, 2:27 PM

Stock of the Week: Micron Technology at the Golden Moment of the Memory Cycle

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits